Frontiers in Cardiovascular Medicine | |
Atrial Fibrillation and Cancer | |
article | |
Ludhmila Abrahao Hajjar1  Silvia Moulin Ribeiro Fonseca1  Theuran Inahja Vicente Machado1  | |
[1] Cancer Institute, University of São Paulo | |
关键词: atrial fibrillation; cancer; anticoagulation; cardiotoxicity; drug-drug interaction; | |
DOI : 10.3389/fcvm.2021.590768 | |
学科分类:地球科学(综合) | |
来源: Frontiers | |
【 摘 要 】
Cancer patients have a higher risk of atrial fibrillation (AF) than general population, the pathophysiology mechanisms involves the pro inflammatory status of immune system in these patients and the exacerbated inflammatory response to cancer treatment and surgeries. Adequate management and prophylaxis for its occurrence are important and reduce morbidity and mortality in this population. There is a challenge in AF related to cancer to predict thromboembolic and bleeding risk in these patients, once standard stroke and hemorrhagic prediction scores are not validated for them. It is used CHA2DS2-VASc and HAS-BLED scores, the same as used in general population. In this review, we demonstrate correlated mechanisms to occurrence AF in cancer patients as well as therapeutic challenges in this population.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202108190001281ZK.pdf | 800KB | download |